Breaking News

WuXi API Facility Passes FDA Inspection

August 18, 2014

To manufacture API for branded commercial drug

WuXiPharmaTech’s subsidiary, Shanghai SynTheAll Pharmaceutical Co. Ltd. (STA), passed an FDA inspection in July for the manufacture of the API for an undisclosed branded commercial drug.
 
This is the first FDA inspection of STA's facilities for the manufacture of an API. The company had previously received FDA approval for the manufacture of an advanced intermediate. STA provides process research to commercial manufacturing.
 
"We are very pleased to have passed a second FDA inspection of our manufacturing facilities," said Dr. Ge Li, chairman and chief executive officer of WuXiPharmaTech. "These favorable outcomes reflect our dedication to maintaining the highest quality standards throughout our organization."

blog comments powered by Disqus
  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • The Western API Industry

    The Western API Industry

    Dr. Enrico T. Polastro, Arthur D. Little||January 28, 2016
    Temporary reprieve or lasting recovery?

  • CMOs: A Flexibility Alternative

    CMOs: A Flexibility Alternative

    Philip K. Burns, CRO-Consulting||January 28, 2016
    A look at how to include CMOs as an option to improve overall flexibility